Canexis Pharma AG holds all relevant authorizations for the manufacture of active pharmaceutical ingredients (APIs) in accordance with EU and PIC/S GMP.
The aim is to produce further cannabis medicines in accordance with the applicable regulations and pharmacopoeias at the highest quality standards, which primarily includes the following plants:
We currently offer the following product portfolio:
In order to always maintain the highest quality, Canexis relies on process knowledge, clean rooms and state-of-the-art systems. The entire value chain from the seedlings to the delivered raw materials is monitored by Canexis. Our in-house analytics support compliance with the highest quality from incoming goods inspection through all processes right up to release for shipping to our customers.
We would be happy to offer you suitable solutions in the area of medical cannabis.
Contact us for a non-binding consultation.
